Ontology highlight
ABSTRACT:
SUBMITTER: Kiga M
PROVIDER: S-EPMC4313120 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
Kiga Masaki M Nakayama Ayako A Shikata Yuki Y Sasazawa Yukiko Y Murakami Ryo R Nakanishi Toshiyuki T Tashiro Etsu E Imoto Masaya M
Scientific reports 20150202
Although clinical studies have evaluated several MEK1/2 inhibitors, it is unlikely that MEK1/2 inhibitors will be studied clinically. BRAF mutations have been proposed as a responder marker of MEK1/2 inhibitors in a preclinical study. However, current clinical approaches focusing on BRAF mutations have shown only moderate sensitivity of MEK1/2 inhibitors. This has led to insufficient support for their promoted clinical adoption. Further characterization of tumors sensitive to MEK inhibitors hold ...[more]